BXP vs. APH, AGY, ANCR, EAH, CEL, VLG, BMK, AVCT, HVO, and 4BB
Should you be buying Beximco Pharmaceuticals stock or one of its competitors? The main competitors of Beximco Pharmaceuticals include Alliance Pharma (APH), Allergy Therapeutics (AGY), Animalcare Group (ANCR), ECO Animal Health Group (EAH), Celadon Pharmaceuticals (CEL), Venture Life Group (VLG), Benchmark (BMK), Avacta Group (AVCT), hVIVO (HVO), and 4basebio (4BB). These companies are all part of the "medical" sector.
Beximco Pharmaceuticals (LON:BXP) and Alliance Pharma (LON:APH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Beximco Pharmaceuticals has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Alliance Pharma received 95 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. However, 64.67% of users gave Beximco Pharmaceuticals an outperform vote while only 62.08% of users gave Alliance Pharma an outperform vote.
In the previous week, Alliance Pharma had 2 more articles in the media than Beximco Pharmaceuticals. MarketBeat recorded 3 mentions for Alliance Pharma and 1 mentions for Beximco Pharmaceuticals. Alliance Pharma's average media sentiment score of 0.25 beat Beximco Pharmaceuticals' score of 0.00 indicating that Alliance Pharma is being referred to more favorably in the news media.
Beximco Pharmaceuticals pays an annual dividend of GBX 3 per share and has a dividend yield of 7.7%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 5.9%. Beximco Pharmaceuticals pays out 3,333.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Alliance Pharma pays out -20,000.0% of its earnings in the form of a dividend.
Alliance Pharma has a consensus price target of GBX 80.75, indicating a potential upside of 137.37%. Given Alliance Pharma's higher probable upside, analysts clearly believe Alliance Pharma is more favorable than Beximco Pharmaceuticals.
1.7% of Beximco Pharmaceuticals shares are held by institutional investors. Comparatively, 66.7% of Alliance Pharma shares are held by institutional investors. 11.8% of Alliance Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Beximco Pharmaceuticals has a net margin of 12.37% compared to Alliance Pharma's net margin of -4.15%. Beximco Pharmaceuticals' return on equity of 10.99% beat Alliance Pharma's return on equity.
Beximco Pharmaceuticals has higher revenue and earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Beximco Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Beximco Pharmaceuticals beats Alliance Pharma on 10 of the 19 factors compared between the two stocks.
Get Beximco Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Beximco Pharmaceuticals Competitors List
Related Companies and Tools